Trial Profile
A Phase 2 Trial of Neoadjuvant Pembrolizumab in Combination With Epacadostat (INCB024360) in Patients With Non-Metastatic Esophageal/Gastroesophageal Squamous Cell and Adenocarcinomas Treated With Neoadjuvant Chemoradiation: A Window-Of-Opportunity Study
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2022
Price :
$35
*
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- 26 Jul 2018 New trial record